郑心田,陈康寅,RHA Seung-Woon,李永健,李广平

• 1:天津医科大学第二医院心脏科
• 2:韩国高丽大学附属九老医院心脏中心
• 3:天津市南开医院心内科

摘要(Abstract)：

目的评价在冠状动脉弥漫性长病变中使用重叠西罗莫司(雷帕霉素)洗脱支架(SES)与重叠紫杉醇洗脱支架(PES)的疗效及安全性。方法研究入选冠状动脉弥漫性长病变患者197例,分别接受重叠SES(CypherTM,75例,110处病变)或PES(TaxusTM,122例,177处病变)。比较两组随访6个月时造影及随访2年时的临床结果。结果随访6个月时造影结果表明,SES组最小管腔直径显著高于PES组(P=0.013);晚期管腔丢失、再狭窄百分比和二元再狭窄率显著低于PES组(P均<0.05)。2年临床随访结果显示,SES组总死亡率、靶病变血运重建、靶血管血运重建及主要不良心脏事件的发生率显著低于PES组(P均<0.05)。多因素回归分析显示,相较于PES,SES是随访2年时总死亡(OR=0.20,95%CI:0.05~0.83,P=0.027)、靶病变重建(OR=0.26,95%CI:0.10~0.73,P=0.010)和主要不良心脏事件(OR=0.38,95%CI:0.18~0.82,P=0.014)的独立保护性预测因素。结论在冠状动脉弥漫性长病变治疗中,相较于重叠使用PES,重叠SES显著改善了6个月时的造影随访结果,并且该结果能转化成为更佳的2年临床随访结果。

关键词(KeyWords)： 弥漫性长病变;紫杉醇洗脱支架;西罗莫司(雷帕霉素)洗脱支架

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郑心田,陈康寅,RHA Seung-Woon,李永健,李广平

参考文献(References)：

• [1]Shinke T,Li J,Chen JP,et al.High incidence of intramural thrombus after overlapping paclitaxel-eluting stent implantation:angioscopic and histopathologic analysis in porcine coronary arteries.Circ Cardiovasc Interv,2008,1:28-35.
• [2]Indermuehle A,Bahl R,Lansky AJ,et al.Drug-eluting balloon angioplasty for in-stent restenosis:a systematic review and metaanalysis of randomised controlled trials.Heart,2013,99:327-333.
• [3]King L,Byrne RA,Mehilli J,et al.Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent:final results of the intracoronary stenting and angiographic restenosis-test equivalence between two drug-eluting stents(ISAR-TEST)trial.Catheter Cardiovasc Interv,2013,81:E23-E28.
• [4]沈松萃,仇兴标,施鸿毓,等.标签内与标签外应用药物洗脱支架对冠心病预后的影响.中国介入心脏病学杂志,2010,18:125-129.
• [5]Kereiakes DJ,Wang H,Popma JJ,et al.Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents:pooled analysis of five clinical trials.J Am Coll Cardiol,2006,48:21-31.
• [6]Degertekin M,Arampatzis CA,Lemos PA,et al.Very long sirolimus-eluting stent implantation for de novo coronary lesions.Am J Cardiol,2004,93:826-829.
• [7]Lee CW,Park KH,Kim YH,et al.Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.Am J Cardiol,2006,98:918-922.
• [8]Chu WW,Kuchulakanti PK,Torguson R,et al.Comparison of clinical outcomes of overlapping sirolimus-versus paclitaxeleluting stents in patients undergoing percutaneous coronary intervention.Am J Cardiol,2006,98:1563-1566.
• [9]Aoki J,Ong AT,Rodriguez Granillo GA,et al."Full metal jacket"(stented length>or=64 mm)using drug-eluting stents for de novo coronary artery lesions.Am Heart J,2005,150:994-999.
• [10]Kim YH,Park SW,Lee SW,et al.Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.Circulation,2006,114:2148-2153.